| Segment Information |
Segment Information The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.
The following table is a summary of segment information for three and nine months ended September 30, 2025 and 2024 (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
For the nine months ended |
|
September 30, 2025 |
|
September 30, 2024 |
|
September 30, 2025 |
|
September 30, 2024 |
| Net revenues |
|
|
|
|
|
|
|
| Diagnostic services |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
| Consumer products |
883 |
|
|
1,416 |
|
|
3,561 |
|
|
5,276 |
|
| Consolidated net revenue |
883 |
|
|
1,416 |
|
|
3,561 |
|
|
5,276 |
|
| Cost of revenue |
|
|
|
|
|
|
|
| Diagnostic services |
7 |
|
|
709 |
|
|
351 |
|
|
1,429 |
|
| Consumer products |
999 |
|
|
492 |
|
|
2,073 |
|
|
3,847 |
|
| Consolidated cost of revenue |
1,006 |
|
|
1,201 |
|
|
2,424 |
|
|
5,276 |
|
| Depreciation and amortization expense |
|
|
|
|
|
|
|
| Diagnostic services |
75 |
|
|
727 |
|
|
614 |
|
|
1,528 |
|
| Consumer products |
623 |
|
|
805 |
|
|
2,235 |
|
|
1,609 |
|
| Total Depreciation and amortization expense |
698 |
|
|
1,532 |
|
|
2,849 |
|
|
3,137 |
|
| Operating and other expenses |
|
|
|
|
|
|
|
| Diagnostic services |
1,163 |
|
|
1,138 |
|
|
2,891 |
|
|
3,162 |
|
| Consumer products |
695 |
|
|
1,160 |
|
|
1,967 |
|
|
2,275 |
|
| Unallocated corporate |
4,317 |
|
|
3,858 |
|
|
8,797 |
|
|
14,739 |
|
| Total operating and other expenses |
6,175 |
|
|
6,156 |
|
|
13,655 |
|
|
20,176 |
|
| Income (loss) from operations, before income taxes |
|
|
|
|
|
|
|
| Diagnostic services |
(1,245) |
|
|
(2,574) |
|
|
(3,856) |
|
|
(6,119) |
|
| Consumer products |
(1,434) |
|
|
(1,041) |
|
|
(2,714) |
|
|
(2,455) |
|
| Unallocated corporate |
(4,317) |
|
|
(3,858) |
|
|
(8,797) |
|
|
(14,739) |
|
| Total loss from operations, before income taxes |
(6,996) |
|
|
(7,473) |
|
|
(15,367) |
|
|
(23,313) |
|
| Income tax (expense) benefit |
157 |
|
|
2,508 |
|
|
(622) |
|
|
7,361 |
|
| Total loss from operations, after income taxes |
(6,839) |
|
|
(4,965) |
|
|
(15,989) |
|
|
(15,952) |
|
| Net loss from continuing operations |
$ |
(6,839) |
|
|
$ |
(4,965) |
|
|
$ |
(15,989) |
|
|
$ |
(15,952) |
|
The following table is a summary of segment information as of September 30, 2025 and December 31, 2024 (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2025 |
|
December 31, 2024 |
| ASSETS |
|
|
|
| Diagnostic services |
$ |
— |
|
|
$ |
26,069 |
|
| Consumer products |
15,552 |
|
|
19,745 |
|
| Unallocated corporate |
50,150 |
|
|
5,804 |
|
| Assets in discontinued operations |
— |
|
|
11,582 |
|
| Total assets |
$ |
65,702 |
|
|
$ |
63,200 |
|
|